Patents
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
04/2003
04/22/2003US6552223 N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them
04/22/2003US6552216 Molecular model for VLA-4 inhibitors
04/22/2003US6552202 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
04/22/2003US6552188 Unsymmetrical cyclic diamine compound
04/22/2003US6552088 Biphenyl derivatives
04/22/2003US6552081 Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
04/22/2003US6552075 Therapeutic compounds and methods of use
04/22/2003US6552071 Methods for treating cell death diseases and inflammation
04/22/2003US6552054 Chromone derivatives, process for the preparation of the same and uses thereof
04/22/2003US6552047 H2 receptor antagonist compounds in combination with nitric oxide donors, compositions and methods of use
04/22/2003US6552043 Benzimidazolinyl piperidines as CGRP ligands
04/22/2003US6552036 3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
04/22/2003US6552031 Synergistic analgesic combination of oxycodone and rofecoxib
04/22/2003US6552020 Compositions including antibiotics and methods for using same
04/22/2003US6552019 Inhibitors of p38
04/22/2003US6552012 Heteroaryl diazabicycloalkanes, their preparation and use
04/22/2003US6552010 Treatment of SLE with dehydroepiandrosterone
04/22/2003US6551822 NL4 tie ligand homologue
04/22/2003US6551615 Capsule containing dexibuprofen (ibuprofen) dissolved in a solubilizer, a potassium salt forming compound, surfactants, co-surfactants, and a viscosity imparter; bioavailability
04/22/2003CA2304784C A transdermal drug delivery system for anti-inflammatory analgesic agent comprising diclofenac diethylammonium salt, and the manufacturing method thereof
04/22/2003CA2287054C 1,3,8-triazaspiro¬4,5|decanone compounds as orl1-receptor agonists
04/22/2003CA2264960C External formulation containing loxoprofen
04/22/2003CA2253869C Substituted oxobutyric acids as matrix metalloprotease inhibitors
04/22/2003CA2068630C Use of protein c or activated protein c
04/17/2003WO2003031939A2 Protein modification and maintenance molecules
04/17/2003WO2003031595A2 Molecules for disease detection and treatment
04/17/2003WO2003031578A2 Mammalian c-type lectins
04/17/2003WO2003031568A2 Intracellular signaling molecules
04/17/2003WO2003031475A2 Antibodies against kdr, their production and uses
04/17/2003WO2003031464A2 Remodeling and glycoconjugation of peptides
04/17/2003WO2003031459A2 Modulation of the expression of genes dependent on stat-1
04/17/2003WO2003031448A1 Reverse-turn mimetics and method relating thereto
04/17/2003WO2003031447A2 Pyrimidine derivatives
04/17/2003WO2003031438A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
04/17/2003WO2003031434A1 Compounds and methods
04/17/2003WO2003031431A1 Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
04/17/2003WO2003031418A1 3,4-dihydro-1h-naphthalene derivatives as a highly selective cyclooxygenase-2 inhibitor
04/17/2003WO2003031414A1 Novel heterocyclic compound and anti-inflammatory agent
04/17/2003WO2003031407A2 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
04/17/2003WO2003031405A2 Methods for the synthesis of substituted purines
04/17/2003WO2003031404A2 Processes for the preparation of substituted isoxazoles and 2-isoxazolines
04/17/2003WO2003031398A1 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
04/17/2003WO2003030993A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
04/17/2003WO2003030944A2 Inhibition of stat-1
04/17/2003WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003WO2003030939A1 Therapies for treating respiratory diseases
04/17/2003WO2003030937A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
04/17/2003WO2003030930A1 Human 3 relaxin
04/17/2003WO2003030929A1 Combination therapies using methyl donors or methyl donor enhancers and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
04/17/2003WO2003030927A2 Use of thymulin-like peptides for making pain-relieving medicines
04/17/2003WO2003030920A1 An antispasmodic agent spaced drug delivery system
04/17/2003WO2003030919A1 Method of obtaining an extract of ginger
04/17/2003WO2003030905A1 Dihydroorotate dehydrogenase inhibitor
04/17/2003WO2003030902A1 Imidazole derivates as anti-inflammatory agents
04/17/2003WO2003030897A1 Pyrrolidinone derivatives
04/17/2003WO2003030889A1 Para-amino benzoic acids as integrin antagonists
04/17/2003WO2003030883A1 Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
04/17/2003WO2003030882A1 Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made thereform
04/17/2003WO2003030878A2 Galenic microparticulate oral formulation
04/17/2003WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003WO2003030875A1 Over-coated chewing gum formulations including tableted center
04/17/2003WO2003030857A1 Enhancing epidermal barrier development in skin
04/17/2003WO2003030833A2 Angiopoietin-2 specific binding agents
04/17/2003WO2003030827A2 Compositions for and methods of treating and preventing sirs/sepsis
04/17/2003WO2003030823A2 Combinations for the treatment of immunoinflammatory disorders
04/17/2003WO2003030616A2 21132, a human g-protein coupled receptor family member and uses therefor
04/17/2003WO2003008457A3 Polysaccharidic esters of retinoic acid
04/17/2003WO2003007875A3 Compounds with analgesic, antipyretic and/or anti-inflammatory activity
04/17/2003WO2003005999A3 Methods of treating cytokine mediated diseases
04/17/2003WO2002098852A3 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
04/17/2003WO2002089770A3 Topical lamellar double membrane structure composition containing n-acyl-ethanolamine and/or a quaternary ammonium salt and/or adenosylmethionine
04/17/2003WO2002085930A3 Immunomodulating agents from parasitic worms and method for isolation thereof
04/17/2003WO2002083700A3 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
04/17/2003WO2002076486A3 Histidine-rich glycoprotein
04/17/2003WO2002072636A3 Crystals of whole antibodies and fragments thereof and methods for making and using them
04/17/2003WO2002070706A3 Interleukin-8 homologous polypeptides and therapeutic uses thereof
04/17/2003WO2002069968A8 New use
04/17/2003WO2002050289A9 Methods for the production of multimeric proteins, and related compositions
04/17/2003WO2002047704A9 Herbal pharmaceutical compositions for treating immunological disorders
04/17/2003WO2002044191A3 Anti-inflammatory compounds derived from pseudopterogorgia elisabethae
04/17/2003WO2002033085A3 Wisp polypeptides and therapeutical applications thereof
04/17/2003WO2002032865A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
04/17/2003WO2002032445A3 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
04/17/2003WO2002029036A3 Lipid metabolism enzymes
04/17/2003WO2002024891A3 B7-like molecules and uses thereof
04/17/2003WO2002020619A9 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
04/17/2003WO2002018445A3 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
04/17/2003WO2002017881A3 Transdermal pharmaceutical delivery composition
04/17/2003WO1999064401A3 Imidazolyl derivatives and their use as somatostatin receptor ligands
04/17/2003US20030073849 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
04/17/2003US20030073845 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
04/17/2003US20030073833 Antiinflammatory agents; anticoagulants
04/17/2003US20030073832 Novel aminophenyl ketone derivatives
04/17/2003US20030073733 Pharmaceutically active compounds and methods of use
04/17/2003US20030073732 Antiinflammatory agents
04/17/2003US20030073727 Central nervous system disorders
04/17/2003US20030073723 Antiinflammatory agents; rheumatic diseases; antiallergens
04/17/2003US20030073720 Tryptase inhibitors
04/17/2003US20030073719 Chiral salt resolution
04/17/2003US20030073718 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease